Zimbabwe has rejected a major American health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for confidential biological samples.
This move came to light after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
A government representative later explained that the US was requesting biological samples for research and profit while was unwilling to guarantee the resulting advantages from future medical innovations.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to reach a agreement acceptable to both sides so the nation's critical HIV treatment initiative can continue.
Wider Context
This development comes after a similar case in Kenya, where a court halted a related health funding agreement following legal challenges were raised about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral deals to boost openness and responsibility.
Based on statements, 16 African countries have to date signed similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data over an extended period, without any equivalent promise of access to any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our nation would supply the raw materials for medical research without any assurance that the final treatments would be accessible to our population should a new disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining systems previously set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This system is intended to ensure that when a nation provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how future co-operation might be structured in a manner that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but urged that talks need to persist given that much of the country's Aids initiatives depended on foreign aid.
"Where technical issues arise, such as those involving data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," it said.
The situation emphasises the complex debate between receiving vital international aid and safeguarding a country's data in an ever more interconnected world.